JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), e359–e386 (2015).
  Medline CASGoogle Scholar
• 2 Grégoire V, Lefèbvre JL, Licitra L et al. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), 184–186 (2010).
  MedlineGoogle Scholar
• 3 Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363(1), 24–35 (2010).
  Medline CASGoogle Scholar
• 4 O'Sullivan B, Huang SH, Su J et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 17(4), 440–451 (2016).
  MedlineGoogle Scholar
• 5 Ang KK, Zhang Q, Rosenthal DI et al. Randomized Phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J. Clin. Oncol. 32(27), 2940–2950 (2014).
  Medline CASGoogle Scholar
• 6 Haddad R, O'Neill A, Rabinowits G et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised Phase III trial. Lancet Oncol. 14(3), 257–264 (2013).
  Medline CASGoogle Scholar
• 7 Cohen EEW, Karrison TG, Kocherginsky M et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J. Clin. Oncol. 32(25), 2735–2743 (2014).
  Medline CASGoogle Scholar
• 8 Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116–1127 (2008).
  Medline CASGoogle Scholar
• 9 Machtay M, Moughan J, Trotti A et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J. Clin. Oncol. 26(21), 3582–3589 (2008).
  Medline CASGoogle Scholar
• 10 Kaufman HL, Russell J, Hamid O et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, Phase II trial. Lancet Oncol. 17(10), 1374–1385 (2016).
  Medline CASGoogle Scholar
• 11 Patel MR, Ellerton J, Infante JR et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN solid tumor): pooled results from two expansion cohorts of an open-label, Phase I trial. Lancet Oncol. 19(1), 51–64 (2017).
  MedlineGoogle Scholar
• 12 Heery CR, O'Sullivan-Coyne G, Madan RA et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN solid tumor): a Phase Ia, multicohort, dose-escalation trial. Lancet Oncol. 18(5), 587–598 (2017). • Phase Ia clinical trial demonstrates the safety of avelumab in previously treated solid tumors.
  Medline CASGoogle Scholar
• 13 Gulley JL, Rajan A, Spigel DR et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN solid tumor): dose-expansion cohort of a multicentre, open-label, Phase Ib trial. Lancet Oncol. 18(5), 599–610 (2017).
  Medline CASGoogle Scholar
• 14 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252–264 (2012).
  Medline CASGoogle Scholar
• 15 Ferris RL. Immunology and immunotherapy of head and neck cancer. J. Clin. Oncol. 33(29), 3293–3304 (2015).
  Medline CASGoogle Scholar
• 16 Bauml J, Seiwert TY, Pfister DG et al. Pembrolizumab for platinum- and cetuximab- refractory head and neck cancer: results from a single-arm, Phase II study. J. Clin. Oncol. 35(14), 1542–1549 (2017).
  Medline CASGoogle Scholar
• 17 Zandberg D, Algazi A, Jimeno A et al. Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, Phase II study. Ann. Oncol. 28(Suppl. 5), mdx374 (2017).
  Google Scholar
• 18 Ferris RL, Blumenschein G, Fayette J et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375(19), 1856–1867 (2016).
  MedlineGoogle Scholar
• 19 Seiwert TY, Burtness B, Mehra R et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, Phase Ib trial. Lancet Oncol. 17(7), 956–965 (2016).
  Medline CASGoogle Scholar
• 20 Chow LQM, Haddad R, Gupta S et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the Phase Ib KEYNOTE-012 expansion cohort. J. Clin. Oncol. 34(32), 3838–3845 (2016).
  Medline CASGoogle Scholar
• 21 Cohen EEW, Harrington K, Le Tourneau C et al. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) Phase III KEYNOTE-040 trial. Ann. Oncol. 28(Suppl. 5), mdx440.040 (2017).
  Google Scholar
• 22 Baxi SS, Dunn LA, Burtness BA. Amidst the excitement: a cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma. Oral Oncol. 62, 147–148 (2016).
  MedlineGoogle Scholar
• 23 Liu K, Tan S, Chai Y et al. Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res. 27(1), 151–153 (2017).
  Medline CASGoogle Scholar
• 24 Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19(7), 813–824 (2007).
  Medline CASGoogle Scholar
• 25 Boyerinas B, Jochems C, Fantini M et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol. Res. 3(10), 1148–1157 (2015).
  Medline CASGoogle Scholar
• 26 Khanna S, Thomas A, Abate-Daga D et al. Malignant mesothelioma effusions are infiltrated by CD3⁺ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J. Thorac. Oncol. 11(11), 1993–2005 (2016).
  MedlineGoogle Scholar
• 27 Fujii R, Friedman ER, Richards J et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget 7(23), 33498–33511 (2016).
  MedlineGoogle Scholar
• 28 Kelly K, Heery CR, Patel MR et al. Avelumab (Msb0010718c; Anti-Pd-L1) in patients with advanced cancer: safety data from 1300 patients enrolled in the Phase Ib Javelin solid tumor trial. J. Clin. Oncol. 34(Suppl. 15), 3055 (2017). • Safety data from 1300 patients enrolled on Phases I and II clinical trials of avelumab in advanced solid tumors.
  Google Scholar
• 29 Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol. Res. 3(5), 436–443 (2015).
  Medline CASGoogle Scholar
• 30 Zamarin D, Holmgaard RB, Subudhi SK et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6(226), 226ra32 (2014).
  MedlineGoogle Scholar
• 31 Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 8(3), 151–160 (2011).
  Medline CASGoogle Scholar
• 32 Zitvogel L, Galluzzi L, Smyth MJ et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39(1), 74–88 (2013).
  Medline CASGoogle Scholar
• 33 de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin. Cancer Res. 20(21), 5384–5391 (2014).
  Medline CASGoogle Scholar
• 34 Spiotto M, Fu Y-X, Weichselbaum RR. The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci. Immunol. 1(3), eaag1266 (2016).
  MedlineGoogle Scholar
• 35 Lee Y, Auh SL, Wang Y et al. Therapeutic effects of ablative radiation on local tumor require CD8⁺ T cells: changing strategies for cancer treatment. Blood 114(3), 589–595 (2009).
  Medline CASGoogle Scholar
• 36 Dovedi SJ, Adlard AL, Lipowska-Bhalla G et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74(19), 5458–5468 (2014).
  Medline CASGoogle Scholar
• 37 Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J. Clin. Oncol. 30(17), 2046–2054 (2012).
  Medline CASGoogle Scholar
• 38 Reck M, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II trial. Ann. Oncol. 24(1), 75–83 (2013).
  Medline CASGoogle Scholar
• 39 Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517–2526 (2011).
  Medline CASGoogle Scholar
• 40 Antonia SJ, Villegas A, Daniel D et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 379(24), 2342–2350 (2018).
  Medline CASGoogle Scholar
• 41 Herbst RS, Baas P, Kim D-W et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027), 1540–1550 (2015).
  MedlineGoogle Scholar
• 42 Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377(20), 1919–1929 (2017). •• In this landmark clinical trial, the addition of a PD-L1 inhibitor improved progression-free survival in locoregionally advanced lung cancer.
  Medline CASGoogle Scholar
• 43 Mehanna H, Wong W-L, McConkey CC et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. N. Engl. J. Med. 374(15), 1444–1454 (2016).
  Medline CASGoogle Scholar
• 44 List MA, D'Antonio LL, Cella DF et al. The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy – head and neck scale. A study of utility and validity. Cancer 77(11), 2294–2301 (1996).
  Medline CASGoogle Scholar
• 45 Janssen MF, Pickard AS, Golicki D et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual. Life Res. 22(7), 1717–1727 (2013).
  Medline CASGoogle Scholar